Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05601050 · ClinicalTrials.gov registry record

Linguistic Predictors of Outcomes in Psychosis

A clinical trial, sponsored by Northwell Health.

Completed
Registry status
77
Enrollment target

NCT05601050: Completed study, sponsored by Northwell Health.

NCT05601050 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05601050 has completed, sponsored by Northwell Health.

COMPLETED
Registry status
77 participants
Enrollment target

Study Summary

Longitudinal observational study of the relationship between speech patterns and clinical symptoms in schizophrenia spectrum disorders.

Primary Outcome

Acoustic and linguistic measures of speech computed based on performance on the Winterlight Speech Assessment.

Interventions

  • OTHER There is no intervention

Trial Details

FieldValue
Enrollment Target 77 participants
Start Date 2021-03-04
Est. Completion 2023-03-01
Northwell Health

370 total trials

What the finished NCT05601050 record still lists

NCT05601050 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 77 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.

NCT05601050 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05601050 about?

NCT05601050 is a clinical study titled "Linguistic Predictors of Outcomes in Psychosis". Longitudinal observational study of the relationship between speech patterns and clinical symptoms in schizophrenia spectrum disorders.

What is the current status of trial NCT05601050?

This trial is currently completed. The enrollment target is 77 participants. The study started on 2021-03-04. Estimated completion is 2023-03-01.

What interventions are being tested in trial NCT05601050?

The interventions under investigation include: There is no intervention (OTHER).

Who is sponsoring clinical trial NCT05601050?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02127398 · 77 participants · Phase 2

    Stool Transplants to Treat Refractory Clostridium Difficile Colitis

  • NCT04159103 · 77 participants · Phase 1

    Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

  • NCT04683003 · 77 participants · Phase 3

    A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

  • NCT05004116 · 77 participants · Phase 1

    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05601050, the US trial registry maintained by the National Library of Medicine. NCT05601050 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.